Orserdu A Menarini Australia Pty Ltd
Product name
Orserdu
Sponsor
Accepted date
Feb-2024
Active ingredients
elacestrant dihydrochloride
Proposed indication
Indicated for the treatment of postmenopausal patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Application type
A (new medicine)
Publication date
Feb-2024